Treatment for peptic ulcer and eradication of helicobacter pylori in patients of the sentinel practice network
DOI:
https://doi.org/10.32385/rpmgf.v21i5.10167Keywords:
Peptic Ulcer, Helicobacter Pylori, Anti-Secreting Agent, «Portuguese Sentinel Network», Eradication TherapyAbstract
Background: Nowadays there is well-established evidence that the existence of a Helicobacter pylori infection is associated with the occurrence of peptic ulcer. Eradication therapies lead to high rates of ulcer healing and lower rates of recurrences. Objective: To characterize the therapeutic regimens for diagnosed peptic ulcer in clinical practice and/or in patients exposed to eradication therapy even without diagnostic of peptic ulcer confirmed by endoscopy. Methodology: A descriptive study was conducted through the «Rede Médicos Sentinela», a research network of general practitioners (GPs) that investigates in several health-related phenomena. Through this network, the most frequently prescribed profiles for peptic ulcer (with endoscopic confirmation) and H.pylori eradication were identified. The study was performed within one year and with the participation of thirty-six GPs. Among the 36.408 patients registered in the GPs list, a sample of 120 patients fulfilled the inclusion criteria. The sample consisted of 75 peptic ulcer patients and 45 patients without confirmation of peptic ulcer but with a H. pylori eradication therapy prescription. Results: The most frequently found ulcer was duodenal, present in 46.7% cases, from which 31.4% were recurrences. Gastric ulcer was identified in 41.4% of the cases being 25.8% recurrent ulcers. In 24.0 % of the cases, H. pylori were identified as being the likely aetiology of the GI disorder. In only 52.0% of the confirmed peptic ulcer patients, a H. pylori eradication therapy was prescribed but in spite of this, only in 94.4% of the patients with a by laboratory test confirmed H. pylori infection, were treated with one eradication regime. Conclusions: The therapeutic regimens followed, in general, the recommendation published about the therapeutic management of peptic ulcer. However, the discordance was found and mainly associated with the dosage and the number of daily administrations of the anti-secreting agent.Downloads
Downloads
Published
Issue
Section
License
The authors will assign to the RPMGF the sole right to publish and distribute the content of the manuscript specified in this declaration via physical, electronic, broadcasting or any other medium that may come into existence. They also grant the RPMGF the right to use and exploit this manuscript, in particular by assigning, selling or licensing its content. This permission is permanent and takes effect from the moment the manuscript is submitted, has the maximum duration allowed by applicable Portuguese or international law and is of worldwide scope. The authors further declare that this assignment is made free of charge. If the RPMGF informs the authors that it is not going to publish their manuscript, the exclusive assignment of rights ceases forthwith.
The authors authorise the RPMGF (or any entity it may appoint) to act on their behalf when it believes that copyright may have been infringed.
